Tech Company Financing Transactions

Breath Therapeutics Funding Round

On 3/9/2017, Breath Therapeutics announced $45.8 million in Series A funding from GIMV, Sofinnova Ventures and Gilde Healthcare Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
Frankfurt, 60326
Germany

Phone

Undisclosed

Website

www.breath.xxii.de

Email Address

[email protected]

Overview

Breath Therapeutics' lead programme is a first-in-class therapeutic/med-tech device combination to treat the Bronchiolitis Obliterans Syndrome (BOS), a life-threatening disease that occurs after 65% of lung transplantations.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jens Stegemann

        

Chief Financial Officer

Gerhard Boerner

        

Chief Financial Officer

Anne Burger

        

Chief Operating Officer

Oliver Denk

        

Browse more venture capital transactions:

Prev: 3/9/2017: Virta Health venture capital transaction
Next: 3/9/2017: LoopMe venture capital transaction

Share this article

About Database of VC Transactions

We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary